BerandaEKSO • NASDAQ
add
Ekso Bionics Holdings Inc
Tutup sebelumnya
$0,79
Rentang hari
$0,72 - $0,78
Rentang tahun
$0,50 - $2,50
Kapitalisasi pasar
16,92Â jt USD
Volume Rata-Rata
1,87Â jt
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Dalam berita
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
(USD) | Sep 2024info | Perubahan Y/Y |
---|---|---|
Pendapatan | 4,13Â jt | -10,38% |
Biaya operasional | 4,85Â jt | -10,01% |
Laba bersih | -2,07Â jt | 38,42% |
Margin laba bersih | -50,18 | 31,30% |
Penghasilan per saham | — | — |
EBITDA | -2,23Â jt | 10,97% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
(USD) | Sep 2024info | Perubahan Y/Y |
---|---|---|
Investasi tunai jangka pdk | 8,29Â jt | -16,55% |
Total aset | 29,21Â jt | -6,33% |
Total liabilitas | 14,34Â jt | -9,96% |
Total ekuitas | 14,87 jt | — |
Saham yang beredar | 22,00 jt | — |
Harga terhadap nilai buku | 1,16 | — |
Tingkat pengembalian aset | -23,48% | — |
Tingkat pengembalian modal | -33,02% | — |
Arus Kas
Perubahan kas bersih
(USD) | Sep 2024info | Perubahan Y/Y |
---|---|---|
Laba bersih | -2,07Â jt | 38,42% |
Kas dari operasi | -2,28Â jt | 32,09% |
Kas dari investasi | -8,00Â rb | 52,94% |
Kas dari pembiayaan | 4,69 jt | — |
Perubahan kas bersih | 2,41Â jt | 171,42% |
Arus kas bebas | -1,11Â jt | 57,80% |
Tentang
Ekso Bionics Holdings Inc. is a company that develops and manufactures powered exoskeleton bionic devices that can be strapped on as wearable robots to enhance the strength, mobility, and endurance of industrial workers and people experiencing paralysis and mobility issues after a brain injury, stroke, multiple sclerosis or spinal cord injury. They enable individuals with any amount of lower extremity weakness, including those who are paralyzed, to stand up and walk.
Ekso Bionics currently focuses in the health and industrial sectors.
The company's first commercially available health product was called EksoGT. Ekso Bionics is the original developer of HULC, now under military development by Lockheed Martin, and the current developers of EksoNR, which allows patients who are relearning to walk the ability to stand and take steps. In December 2022, Ekso Bionics acquired the Human Motion & Control business unit from Parker Hannifin which includes the Indego product line. This acquisition allowed Ekso Bionics to begin selling exoskeletons to those who have an SCI and want a personal exoskeleton to walk at home and in their community. Wikipedia
CEO
Didirikan
2005
Kantor pusat
Situs
Karyawan
70